MEFV gene mutations in Turkish children with juvenile idiopathic arthritis

Comak E., Dogan C. S., AKMAN S., KOYUN M., Gokceoglu A. U., KESER İ.

EUROPEAN JOURNAL OF PEDIATRICS, cilt.172, sa.8, ss.1061-1067, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 172 Sayı: 8
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00431-013-2003-x
  • Dergi Adı: EUROPEAN JOURNAL OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1061-1067
  • Anahtar Kelimeler: MEFV mutations, Children, Juvenile idiopathic arthritis, FAMILIAL MEDITERRANEAN FEVER, ANKYLOSING-SPONDYLITIS, DISEASE, PREVALENCE, INFLAMMATION, E148Q
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Mutations of the Mediterranean fever (MEFV) gene, which encodes pyrin protein, leads to familial Mediterranean fever (FMF) and a connection between MEFV mutations and rheumatic diseases has been suggested. The aim of this study was to explore the frequency and clinical significance of MEFV mutations in children with juvenile idiopathic arthritis (JIA). In this study, children with JIA, who had no typical symptoms of FMF, were screened for the mutations in exons 2 and 10 of the MEFV gene by direct sequencing. A total of 96 children, 56 girls (58.3 %), with a median age of 11 years (2-18 years) were included. Patients were classified according to JIA subgroups as oligoarthritis in 43 (44.8 %), rheumatoid factor-negative polyarthritis in 22 (22.9 %), rheumatoid factor-positive polyarthritis in 2 (2.1 %), systemic arthritis in 12 (12.5 %) patients, enthesitis-related arthritis in 16 (16.7 %), and psoriatic arthritis 1 (1.04 %). A total of 31 children (32.3 %) had MEFV mutations: 25 heterozygous, 2 homozygous, and 4 compound heterozygous. There were 22 (11.4 %) exon 10 mutations (M694V, R761H, K695R, V726A, R653H) and 15 (7.8 %) exon 2 mutations (E148Q, G304R, E148V, T267I). The allele frequencies of MEFV mutations were found to be 19.27 %, which is higher than the general population [p = 0.03, (odds ratio (OR):1.93, 95 % confidence interval (CI): 1.09-3.41)]. MEFV mutation carrier rates were significantly higher in antinuclear antibody (ANA) negative than in ANA positive patients [p = 0.01, (OR: 0.25, 95 % CI: 0.085-0.74)] and in males than in females [p = 0.001, (OR: 0.197, 95 % CI: 0.078-0.495)]. Also, there was a statistically significant difference between the MEFV mutation carrier rates and the subgroups of JIA (p = 0.005). Conclusion: These findings suggest that mutations of the MEFV gene may be responsible for rheumatic diseases other than FMF, and patients with JIA especially males, ANA negatives, and ERA subgroups should be screened for MEFV gene mutations in countries where FMF is frequent.